Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2024
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III TrialDomenica Lorusso, Francesco Raspagliesi, Dominique Ronzulli, et al.
Gynecologic Oncology|October 9, 2016
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19)Claudia Marchetti, Gabriella Ferrandina, Gennaro Cormio, et al.
Lancet (London, England)|June 14, 2025
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trialSheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, et al.
Breast (Edinburgh, Scotland)|July 23, 2024
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER studyLuca Arecco, Maria Maddalena Latocca, Eva Blondeaux, et al.
The Lancet. Oncology|April 18, 2015
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trialSandro Pignata, Domenica Lorusso, Giovanni Scambia, et al.
Cancers|February 25, 2022
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal AntibodiesAnna Maria Rachiglio, Laura Forgione, Raffaella Pasquale, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2019
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancerLucio Crinò, Giuseppe Bronte, Paolo Bidoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2024
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE StudyCarlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.
The Lancet. Oncology|September 20, 2021
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Pageof 9